Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
| ▸ | F2R | P25116 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22004969 | 0.95 | BCHE (0.34) | BCHEKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL11974081 | 0.90 | MAPT (0.31) | BCHESMN1; SMN2 | |
| SCHEMBL11974087 | 0.90 | MAPT (0.31) | BCHESMN1; SMN2 | |
| SCHEMBL11974084 | 0.90 | MAPT (0.31) | BCHESMN1; SMN2 | |
| SCHEMBL12023144 | 0.82 | SMN1; SMN2 (0.42) | BCHEKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL25405239 | 0.81 | ALDH1A1 (0.46) | BCHEKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL25401470 | 0.81 | ALDH1A1 (0.46) | BCHEKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL3322339 | 0.79 | HPGD (0.40) | BCHEALDH1A1SMN1; SMN2ITGB3ITGA2B | |
| SCHEMBL2847700 | 0.79 | HPGD (0.40) | BCHEALDH1A1SMN1; SMN2ITGB3ITGA2B | |
| SCHEMBL971781 | 0.79 | HPGD (0.40) | BCHEALDH1A1SMN1; SMN2ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776408-B1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LTD (GB) | 2019-11-06 | — | — | EP | disclosed |
| US-10039759-B2 | Quinolines as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2018-08-07 | — | — | US | disclosed |
| US-10039759-B2 | Quinolines as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2018-08-07 | — | — | US | disclosed |
| EP-2776397-B1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2017-11-29 | — | — | EP | disclosed |
| US-9439896-B2 | Quinolines as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2016-09-13 | — | — | US | disclosed |
| US-9439896-B2 | Quinolines as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2016-09-13 | — | — | US | disclosed |
| US-20160220564-A1 | SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160220564-A1 | SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-9303029-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-04-05 | — | — | US | disclosed |
| US-9303029-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-04-05 | — | — | US | disclosed |
| US-9145394-B2 | — | — | 2015-09-29 | — | — | US | disclosed |
| US-20150031669-A1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2015-01-29 | — | — | US | disclosed |
| US-20150031669-A1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2015-01-29 | — | — | US | disclosed |
| US-20140296236-A1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-20140296236-A1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-20130267525-A1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267525-A1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2013061081-A1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013061074-A1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012073017-A1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039759-B2 | Quinolines as FGFR kinase modulators | FGFR1, FGFR3, FGFR2 | BCHE 4293/4885KDM4E 1082/4885ALDH1A1 1595/4885 |
| US-20160220564-A1 | SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | BCHE 3071/4885KDM4E 969/4885ALDH1A1 1849/4885 |
| US-20150031669-A1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | FGFR1, FGFR4, FGFR3 | BCHE 4322/4885KDM4E 728/4885ALDH1A1 1726/4885 |
| US-20140296236-A1 | QUINOLINES AS FGFR KINASE MODULATORS | FGFR1, FGFR2, FGFR3 | BCHE 4335/4885KDM4E 1048/4885ALDH1A1 1527/4885 |
| US-20130267525-A1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | FGFR1, FGFR4, FGFR3 | BCHE 3871/4885KDM4E 761/4885ALDH1A1 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.